Advanced diagnostic testing, treatments and technologies
A reputation for sensitivity and responsiveness
Innovative clinical trials
The backing of a major research program with immediate translation to patient care
What sets Penn's GI Cancer Risk Evaluation Program apart?
Penn’s GI Cancer Risk Evaluation Program is distinguished in a number of ways including:
One of the first cancer centers in the country to establish a GI Cancer Risk Evaluation Program.
Our nationally prominent GI scientists are funded by the National Cancer Institute to conduct research on the biology of GI cancers, risk factors, differences in cancer risk among ethnic populations, and treatment advances, ensuring that the latest discovery is translated to better patient care immediately.
Our scientific leadership is recognized and supported by the National Colorectal Cancer Research Alliance (NCCRA), founded by Katie Couric and Lilly Tartikoff.